Table 1.
Patient characteristics.
| External Beam Radiation Therapy | P value* | Brachytherapy | P value* | |||
|---|---|---|---|---|---|---|
|
| ||||||
| No NADT (N=202) | NADT (N=86) | No NADT (n = 271) | NADT (n = 14) | |||
|
| ||||||
| Age - yr | 0.03 | 0.57 | ||||
| Median | 69 | 71 | 66 | 67 | ||
| Range | 45 – 83 | 50 – 85 | 45 – 81 | 52 – 79 | ||
| Age group – no. (%) | 0.07 | 0.88 | ||||
| <60 | 31 (15) | 10 (12) | 60 (22) | 2 (14) | ||
| 60–69 | 88 (44) | 28 (32) | 130 (48) | 7 (50) | ||
| >70 | 83 (41) | 48 (56) | 81 (30) | 5 (36) | ||
|
| ||||||
| Race | 0.87 | 0.34 | ||||
| White | 162 (81) | 71 (85) | 235 (88) | 11 (7) | ||
| Black | 35 (18) | 13 (15) | 27 (10) | 3 (21) | ||
| Other | 2 (1) | 0 (0) | 4 (2) | 0 (0) | ||
|
| ||||||
| Mean number of coexisting illnesses | 1.5 ± 1.3 | 1.4 ± 1.2 | 0.39 | 1.3 ± 1.1 | 1.5 ± 1.1 | 0.37 |
|
| ||||||
| Mean BMI | 28.6 ± 5.3 | 28.7 ± 5.8 | 0.80 | 28.4 ± 4.6 | 28.9 ± 4.8 | 0.76 |
|
| ||||||
| Mean prostate size - mL | 48.9 ± 26.0 | 51.4 ± 34.3 | 0.83 | 38.8 ± 17.7 | 56.7 ± 12.8 | <0.0001 |
|
| ||||||
| PSA - ng/mL | <0.0001 | 0.33 | ||||
| Median | 5.9 | 9.1 | 5.0 | 6.5 | ||
| Range | 0.5 – 25.8 | 1.6 – 99.3 | 0.6 – 26.4 | 2.1 – 44 | ||
| Group | 0.0005 | 0.15 | ||||
| <4 | 36 (18) | 11 (13) | 59 (22) | 4 (29) | ||
| 4–10 | 133 (66) | 43 (50) | 199 (73) | 8 (57) | ||
| >10 | 33 (16) | 32 (37) | 13 (5) | 2 (14) | ||
|
| ||||||
| Gleason score – no. (%) | <0.0001 | 0.18 | ||||
| <7 | 123 (61) | 7 (8) | 210 (77) | 8 (57) | ||
| 7 | 77 (38) | 42 (49) | 58 (22) | 6 (43) | ||
| >7 | 2 (1) | 37 (43) | 2(1) | 0 (0) | ||
|
| ||||||
| Clinical stage – no. (%) | <0.0001 | 0.47 | ||||
| T1 | 157 (78) | 45 (52) | 228 (84) | 11 (79) | ||
| T2 | 45 (22) | 41 (48) | 42 (16) | 3 (21) | ||
|
| ||||||
| Mean proportion of biopsy cores with cancer - % | 0.3 ± 0.2 | 0.4 ± 0.3 | 0.0001 | 0.3 ± 0.2 | 0.2 ± 0.2 | 0.42 |
|
| ||||||
| Overall cancer severity — no. (%) | <0.0001 | 0.07 | ||||
| Low risk | 99 (49) | 2 (2) | 196 (73) | 7 (50) | ||
| Intermediate risk | 97 (48) | 33 (39) | 70 (26) | 6 (43) | ||
| High risk | 6 (3) | 51 (59) | 4 (1) | 1 (7) | ||
|
| ||||||
| Minimum dose PTV (Gy) | 0.01 | N/A | N/A | |||
| Median | 70 | 73 | ||||
| Range | 48 – 90 | 41 – 77 | ||||
|
| ||||||
| Maximum dose PTV (Gy) | 0.79 | N/A | N/A | |||
| Median | 80 | 81 | ||||
| Range | 45 – 107 | 46 –90 | ||||
|
| ||||||
| IMRT – no. (%) | 0.40 | N/A | N/A | |||
| Yes | 162 (85) | 71 (89) | ||||
| No | 29 (15) | 9 (11) | ||||
|
| ||||||
| Pelvic lymph nodes treated no. (%) | <0.0001 | N/A | N/A | |||
| Yes | 7 (4) | 25 (31) | ||||
| No | 184 (96) | 55 (69) | ||||
|
| ||||||
| Prescribed BT dose (Gy) | N/A | N/A | 0.77 | |||
| Median | 144 | 144 | ||||
| Range | 80 – 145 | 137 – 145 | ||||
|
| ||||||
| D90 ETV (Gy) | N/A | N/A | 0.51 | |||
| Median | 152 | 158 | ||||
| Range | 12–346 | 116–178 | ||||
|
| ||||||
| V100 ETV (%) | N/A | N/A | 0.60 | |||
| Median | 93 | 94 | ||||
| Range | 69 – 100 | 81 – 99 | ||||
Abbreviations: ETV = Evaluation Target Volume, Post Implant; PTV = Planning Target Volume; BT =Brachytherapy